Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $754.00 by Analysts at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target lowered by research analysts at Morgan Stanley from $755.00 to $754.00 in a report released on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target would indicate a potential upside of 32.81% from the company's previous close.

REGN has been the subject of a number of other research reports. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday, June 2nd. Finally, Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $823.54.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $7.98 during trading hours on Thursday, reaching $567.74. 844,505 shares of the stock were exchanged, compared to its average volume of 913,803. The stock has a 50 day moving average of $545.98 and a two-hundred day moving average of $621.52. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market cap of $61.30 billion, a P/E ratio of 14.45, a price-to-earnings-growth ratio of 2.06 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business posted $9.55 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Marietta Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after buying an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $4,915,000. Intact Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $356,000. Rhenman & Partners Asset Management AB lifted its holdings in Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after purchasing an additional 4,457 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.